Study of Matuzumab and Gemcitabine in Pancreatic Cancer
Author Information
Author(s): Graeven U, Kremer B, Südhoff Th, Killing B, Rojo F, Weber D, Tillner J, ünal C, Schmiegel W
Primary Institution: Ruhr University Bochum
Hypothesis
Can matuzumab be safely administered with gemcitabine to patients with advanced pancreatic cancer?
Conclusion
The combination of matuzumab and gemcitabine is well tolerated and may enhance treatment activity in advanced pancreatic cancer.
Supporting Evidence
- Severe treatment-related toxicities were limited to grade 3 neutropenia and leucopenia.
- Partial response or stable disease occurred in eight of 12 evaluated patients.
- Matuzumab inhibited phosphorylated EGFR and affected receptor-dependent signaling.
Takeaway
This study tested a new medicine called matuzumab with another medicine called gemcitabine to see if they work better together for people with a serious type of cancer. It looks like they do!
Methodology
Patients received escalating doses of matuzumab combined with standard-dose gemcitabine, and various safety and efficacy parameters were evaluated.
Limitations
The study was small and not randomized, which may limit the generalizability of the results.
Participant Demographics
Patients had untreated stage III or IV pancreatic cancer, with a median age of 64 years and a mix of genders.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website